Is OjeMDA (tovorafenib) on the market?

OjeMDA (tovorafenib) is a drug used to treat glioma under the trade name Ojemda; it is a selective type II RAF kinase inhibitor with anti-tumor activity, in the United States in April 2024Obtained approval from the U.S. Food and Drug Administration (FDA) for medical use and is the first systemic therapy approved to treat child patients with BRAF rearranged (including fusion) low-grade glioma.

Generally, these tumors occur in one part of the brain and are unresectable but still put the patient at high risk for problems related to vision, long-term neurocognitive status, movement, strength, coordination, or endocrine function of the brain. OjeMDA This systemic therapy has BRAF rearrangement effect. BRAF oncogenic mutations in cancer drive dysregulated cell growth, proliferation and differentiation. OjeMDAinhibits BRAF and blocks dysregulated signaling pathways associated with cancer cell growth and survival. This drug works by stopping the growth of tumors that cannot be surgically removed, with the goal of minimizing harm while maintaining a good quality of life.

OjeMDA is an oral inhibitor available in tablet or liquid form. The recommended dose is based on body surface area and is administered once weekly. It can be taken with food, which is not safe with other oral targeted therapies. The most common adverse reactions to tovofenib include rash, hair color changes, fatigue, viral infection, vomiting, headache, bleeding, pyrexia, dry skin, constipation, nausea, acneiform dermatitis, and upper respiratory tract infection.

The original drug OjeMDA has not been launched in China and has not been sold in other regions except the United States. Domestic patients cannot purchase this drug. Due to its short time on the market, its price is still unclear.